Hyalohyphomycoses (hyaline moulds)

Essentials of Clinical Mycology: Second Edition

Volumn , Issue , 2011, Pages 281-304

  Torres, Harrys A ^a   Kontoyiannis, Dimitrios P ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84864453841     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-6640-7_16     Document Type: Chapter

References (267)

1. Ajello L. Hyalohyphomycosis and phaeohyphomycosis: Two global disease entities of public health importance. Eur J Epidemiol. 1986;2:243-51.
2. Rippon J. Hyalohyphomycosis, pythiosis, miscellaneous and rare mycoses, and algoses. In: Rippon JW, editor. Medical Mycology. 3rd ed. Philadelphia: W. B. Saunders Company; 1988. p. 714-45.
3. Anaissie EJ, Bodey GP, Rinaldi MG. Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis. 1989;8:323-30.
4. Liu K, Howell DN, Perfect JR, Schell WA. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology. Am J Clin Pathol. 1998;109:45-54.
5. Alanio A, Brethon B. Feuilhade de Chauvin M, et al. Invasive pulmonary infection due to Trichoderma longibrachiatum mimicking invasive Aspergillosis in a neutropenic patient successfully treated with voriconazole combined with caspofungin Clin Infect Dis. 2008;46:e116-8.
6. Chamilos G, Kontoyiannis DP. Voriconazole-resistant disseminated Paecilomyces variotii infection in a neutropenic patient with leukaemia on voriconazole prophylaxis. J Infect. 2005;51:e225-8.
7. Mattei D, Mordini N, Lo Nigro C, et al. Successful treatment of Acremonium fungemia with voriconazole. Mycoses. 2003; 46:511-4.
8. Schinabeck MK, Ghannoum MA. Human hyalohyphomycoses: A review of human infections due to Acremonium spp., Paecilomyces spp., Penicillium spp., and Scopulariopsis spp. J Chemother. 2003;15 Suppl 2:5-15.
9. Young NA, Kwon-Chung KJ, Kubota TT, Jennings AE, Fisher RI. Disseminated infection by Fusarium moniliforme during treatment for malignant lymphoma. J Clin Microbiol. 1978;7:589-94.
10. Anaissie E, Kantarjian H, Ro J, et al. The emerging role of Fusarium infections in patients with cancer. Medicine (Baltimore). 1988;67:77-83.
11. Walsh TJ, Groll AH. Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis. 1999;1:247-61.
12. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management. Blood. 1997;90:999-1008.
13. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909-17.
14. Girmenia C, Pagano L, Corvatta L, Mele L, del Favero A, Martino P. The epidemiology of fusariosis in patients with haematological diseases. Gimema Infection Programme. Br J Haematol. 2000;111:272-6.
15. Torres HA, Raad II, Kontoyiannis DP. Infections caused by Fusarium species. J Chemother. 2003;15 Suppl 2:28-35.
16. Guarro J, Gene J. Opportunistic fusarial infections in humans. Eur J Clin Microbiol Infect Dis. 1995;14:741-54.
17. Nir-Paz R, Strahilevitz J, Shapiro M, et al. Clinical and epidemiological aspects of infections caused by Fusarium species: A collaborative study from Israel. J Clin Microbiol. 2004;42:3456-61.
18. Azor M, Gene J, Cano J, et al. In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum. Antimicrob Agents Chemother. 2008;52:2228-31.
19. Campos S, Caramori M, Teixeira R, et al. Bacterial and fungal pneumonias after lung transplantation. Transplant Proc. 2008;40:822-4.
20. Trabasso P, Vigorito A, De Souza C, et al. Invasive fungal infection in hematopoietic stem cell transplant recipients at a Brazilian university hospital. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy 2001 Chicago, IL; 2001.
21. Nucci M, Marr KA, Queiroz-Telles F, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2004;38:1237-42.
22. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev. 1996;9:499-511.
23. Squier C, Yu VL, Stout JE. Waterborne nosocomial infections. Curr Infect Dis Rep. 2000;2:490-6.
24. Anaissie EJ, Kuchar RT, Rex JH, et al. Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: A new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis. 2001;33:1871-8.
25. Kivivuori SM, Hovi L, Vettenranta K, Saarinen-Pihkala UM. Invasive fusariosis in two transplanted children. Eur J Pediatr. 2004;163:692-3.
26. Raad I, Tarrand J, Hanna H, et al. Epidemiology, molecular mycology, and environmental sources of Fusarium infection in patients with cancer. Infect Control Hosp Epidemiol. 2002;23:532-7.
27. Alastruey-Izquierdo A, Cuenca-Estrella M, Monzon A, Mellado E, Rodriguez-Tudela JL. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother. 2008;61:805-9.
28. Tortorano AM, Prigitano A, Dho G, et al. Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy. Antimicrob Agents Chemother. 2008;52:2683-5.
29. Summerbell RC, Schroers HJ. Analysis of phylogenetic relationship of Cylindrocarpon lichenicola and Acremonium falciforme to the Fusarium solani species complex and a review of similarities in the spectrum of opportunistic infections caused by these fungi. J Clin Microbiol. 2002;40:2866-75.
30. Guarro J, Rubio C, Gene J, et al. Case of keratitis caused by an uncommon Fusarium species. J Clin Microbiol. 2003;41:5823-6.
31. Cordoba S, Rodero L, Vivot W, Abrantes R, Davel G, Vitale RG. In vitro interactions of antifungal agents against clinical isolates of Fusarium spp. Int J Antimicrob Agents. 2008;31:171-4.
32. Mayayo E, Pujol I, Guarro J. Experimental pathogenicity of four opportunist Fusarium species in a murine model. J Med Microbiol. 1999;48:363-6.
33. Nelson PE, Dignani MC, Anaissie EJ. Taxonomy, biology, and clinical aspects of Fusarium species. Clin Microbiol Rev. 1994;7:479-504.
34. Ponton J, Ruchel R, Clemons KV, et al. Emerging pathogens. Med Mycol. 2000;38 Suppl 1:225-36.
35. Etzel RA. Mycotoxins. JAMA. 2002;287:425-7.
36. Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect. 2001;7 Suppl 2:8-24.
37. Gong YY, Torres-Sanchez L, Lopez-Carrillo L, et al. Association between tortilla consumption and human urinary fumonisin B1 levels in a Mexican population. Cancer Epidemiol Biomark Prev. 2008;17:688-94.
38. Pitt JI. Toxigenic fungi: Which are important? Med Mycol. 2000;38 Suppl 1:17-22.
39. Campo M, Lewis R, Kontoyiannis DP. Invasive fusariosis in patients with hematologic malignancy at MD Anderson Cancer Center: The last decade. In: Abstracts of the 47th Annual Meeting of the Infectious Diseases Society of America 2009; Philadelphia, Pennsylvania; 2009.
40. Girmenia C, Iori AP, Boecklin F, et al. Fusarium infections in patients with severe aplastic anemia: Review and implications for management. Haematologica. 1999;84:114-8.
41. Torres HA, Bodey GP, Rolston KV, Kantarjian HM, Raad II, Kontoyiannis DP. Infections in patients with aplastic anemia: experience at a tertiary care cancer center. Cancer. 2003;98:86-93.
42. Sagnelli C, Fumagalli L, Prigitano A, Baccari P, Magnani P, Lazzarin A. Successful voriconazole therapy of disseminated Fusarium verticillioides infection in an immunocompromised patient receiving chemotherapy. J Antimicrob Chemother. 2006;57:796-8.
43. Mansoory D, Roozbahany NA, Mazinany H, Samimagam A. Chronic Fusarium infection in an adult patient with undiagnosed chronic granulomatous disease. Clin Infect Dis. 2003;37:e107-8.
44. Winn RM, Gil-Lamaignere C, Roilides E, et al. Effects of interleukin- 15 on antifungal responses of human polymorphonuclear leukocytes against Fusarium spp. and Scedosporium spp. Cytokine. 2005;31:1-8.
45. Lamaris GA, Chamilos G, Lewis RE, Kontoyiannis DP. Virulence studies of Scedosporium and Fusarium species in Drosophila melanogaster. J Infect Dis. 2007;196:1860-4.
46. Lionakis MS, Lewis RE, May GS, et al. Toll-deficient Drosophila flies as a fast, high-throughput model for the study of antifungal drug efficacy against invasive aspergillosis and Aspergillus virulence. J Infect Dis. 2005;191:1188-95.
47. Goldblum D, Frueh BE, Zimmerli S, Bohnke M. Treatment of postkeratitis Fusarium endophthalmitis with amphotericin B lipid complex. Cornea. 2000;19:853-6.
48. Chang DC, Grant GB, O'Donnell K, et al. Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution. JAMA. 2006;296:953-63.
49. Girmenia C, Arcese W, Micozzi A, Martino P, Bianco P, Morace G. Onychomycosis as a possible origin of disseminated Fusarium solani infection in a patient with severe aplastic anemia. Clin Infect Dis. 1992;14:1167.
50. Kontoyiannis D. Mycetoma. In: Goldman L BJ, eds., ed. Cecil Textbook of Medicine. Philadelphia: W. B. Saunders; 2004:2067-8.
51. Wheeler MS, McGinnis MR, Schell WA, Walker DH. Fusarium infection in burned patients. Am J Clin Pathol. 1981;75:304-11.
52. Assaf C, Goerdt S, Seibold M, Orfanos C. Clinical picture. Cutaneous hyalohyphomycosis. Lancet. 2000;356:1185.
53. Marom EM, Holmes AM, Bruzzi JF, Truong MT, O'Sullivan PJ, Kontoyiannis DP. Imaging of pulmonary fusariosis in patients with hematologic malignancies. AJR Am J Roentgenol. 2008;190:1605-9.
54. Merz WG, Karp JE, Hoagland M, Jett-Goheen M, Junkins JM, Hood AF. Diagnosis and successful treatment of fusariosis in the compromised host. J Infect Dis. 1988;158:1046-55.
55. Richardson SE, Bannatyne RM, Summerbell RC, Milliken J, Gold R, Weitzman SS. Disseminated fusarial infection in the immunocompromised host. Rev Infect Dis. 1988;10:1171-81.
56. Minor Jr. RL, Pfaller MA, Gingrich RD, Burns LJ. Disseminated Fusarium infections in patients following bone marrow transplantation. Bone Marrow Transplant. 1989;4:653-8.
57. el-Ani AS. Disseminated infection caused by Fusarium solani in a patient with aplastic anemia. NY State J Med. 1990;90:609-10.
58. Fang CT, Chang SC, Tang IL, et al. Fusarium solani fungemia in a bone marrow transplant recipient. J Formos Med Assoc. 1997; 96:129-33.
59. Segal BH, Walsh TJ, Liu JM, Wilson JD, Kwon-Chung KJ. Invasive infection with Fusarium chlamydosporum in a patient with aplastic anemia. J Clin Microbiol. 1998;36:1772-6.
60. Mattiuzzi GN, Kantarjian H, O'Brien S, et al. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy. Cancer. 2004;100: 568-73.
61. Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother. 2006;50:143-7.
62. Cho CT, Vats TS, Lowman JT, Brandsberg JW, Tosh FE. Fusarium solani infection during treatment for acute leukemia. J Pediatr. 1973;83:1028-31.
63. Bodey GP, Boktour M, Mays S, et al. Skin lesions associated with Fusarium infection. J Am Acad Dermatol. 2002;47:659-66.
64. Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: Implications for diagnosis and management. Clin Infect Dis. 2002;35:909-20.
65. Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev. 1997;10:86-124.
66. Sampathkumar P, Paya CV. Fusarium infection after solid-organ transplantation. Clin Infect Dis. 2001;32:1237-40.
67. Lodato F, Tame MR, Montagnani M, et al. Systemic fungemia and hepatic localizations of Fusarium solani in a liver transplanted patient: An emerging fungal agent. Liver Transplant. 2006;12:1711-4.
68. Anandi V, Vishwanathan P, Sasikala S, Rangarajan M, Subramaniyan CS, Chidambaram N. Fusarium solani breast abscess. Indian J Med Microbiol. 2005;23:198-9.
69. Walsh TJ, Francesconi A, Kasai M, Chanock SJ. PCR and singlestrand conformational polymorphism for recognition of medically important opportunistic fungi. J Clin Microbiol. 1995; 33:3216-20.
70. Hennequin C, Abachin E, Symoens F, et al. Identification of Fusarium species involved in human infections by 28S rRNA gene sequencing. J Clin Microbiol. 1999;37:3586-9.
71. Macedo DP, Neves RP, Fontan J, Souza-Motta CM, Lima D. A case of invasive rhinosinusitis by Fusarium verticillioides (Saccardo) Nirenberg in an apparently immunocompetent patient. Med Mycol. 2008;46:499-503.
72. Hayden RT, Isotalo PA, Parrett T, et al. In situ hybridization for the differentiation of Aspergillus, Fusarium, and Pseudallescheria species in tissue section. Diagn Mol Pathol. 2003;12:21-6.
73. Kontoyiannis DP, Sumoza D, Tarrand J, Bodey GP, Storey R, Raad II. Significance of aspergillemia in patients with cancer: A 10-year study. Clin Infect Dis. 2000;31:188-9.
74. Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal susceptibility testing: Practical aspects and current challenges. Clin Microbiol Rev. 2001;14:643-58.
75. Capilla J, Ortoneda M, Pastor FJ, Guarro J. In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi. Antimicrob Agents Chemother. 2001;45:2635-7.
76. Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet. 2002;359:1135-44.
77. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi: Approved Standard, 2nd ed. M38-A2. In: Clinical and Laboratory Standards Institute Wayne, PA, USA; 2008.
78. Speeleveld E, Gordts B, Van Landuyt HW, De Vroey C, Raes- Wuytack C. Susceptibility of clinical isolates of Fusarium to antifungal drugs. Mycoses. 1996;39:37-40.
79. Marco F, Pfaller MA, Messer SA, Jones RN. In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi. Mycopathologia. 1998;141:73-7.
80. Li RK, Rinaldi MG. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrob Agents Chemother. 1999;43:1401-5.
81. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother. 2001;45:327-30.
82. Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother. 1998;42:741-5.
83. Arikan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex JH. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol. 1999;37:3946-51.
84. Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 2002;46:1032-7.
85. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia. 2001;150:101-15.
86. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob Agents Chemother. 2002;46:3298-300.
87. Minassian B, Huczko E, Washo T, Bonner D, Fung-Tomc J. In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates. Clin Microbiol Infect. 2003;9:1250-2.
88. Espinel-Ingroff A, Johnson E, Hockey H, Troke P. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies. J Antimicrob Chemother. 2008;61:616-20.
89. Roilides E, Lyman CA, Armstrong D, Stergiopoulou T, Petraitiene R, Walsh TJ. Deoxycholate amphotericin B and amphotericin B lipid complex exert additive antifungal activity in combination with pulmonary alveolar macrophages against Fusarium solani. Mycoses. 2006;49:109-13.
90. Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1, 007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother. 2008;52:1396-400.
91. Ortoneda M, Capilla J, Pastor FJ, Pujol I, Guarro J. Efficacy of liposomal amphotericin B in treatment of systemic murine fusariosis. Antimicrob Agents Chemother. 2002;46:2273-5.
92. Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743, 872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol. 1998;36:2950-6.
93. Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother. 2000; 44:57-62.
94. Isham N, Ghannoum MA. Determination of MICs of aminocandin for Candida spp. and filamentous fungi. J Clin Microbiol. 2006;44:4342-4.
95. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Monzon A, Buitrago MJ, Rodriguez-Tudela JL. Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. Antimicrob Agents Chemother. 2009;53:2192-5.
96. Lamaris GA, Lewis RE, Chamilos G, et al. Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis. 2008;198:186-92.
97. Lionakis MS, Lewis RE, Samonis G, Kontoyiannis DP. Pentamidine is active in vitro against Fusarium species. Antimicrob Agents Chemother. 2003;47:3252-9.
98. Li L, Wang Z, Li R, Luo S, Sun X. In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients. Am J Ophthalmol. 2008;146:724-8.
99. Ortoneda M, Capilla J, Javier Pastor F, Pujol I, Guarro J. In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. Diagn Microbiol Infect Dis. 2004;48:69-71.
100. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother. 2002;46:245-7.
101. Stern GA. In vitro antibiotic synergism against ocular fungal isolates. Am J Ophthalmol. 1978;86:359-67.
102. Clancy CJ, Nguyen MH. The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis. J Antimicrob Chemother. 1998;41:127-30.
103. Gorman SR, Magiorakos AP, Zimmerman SK, Craven DE. Fusarium oxysporum pneumonia in an immunocompetent host. South Med J. 2006;99:613-6.
104. Kontoyiannis DP, Bodey GP, Hanna H, et al. Outcome determinants of fusariosis in a tertiary care cancer center: The impact of neutrophil recovery. Leuk Lymphoma. 2004;45:139-41.
105. Nucci M, Anaissie EJ, Queiroz-Telles F, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer. 2003;98:315-9.
106. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998;26:1383-96.
107. Cudillo L, Tendas A, Picardi A, et al. Successful treatment of disseminated fusariosis with high dose liposomal amphotericin-B in a patient with acute lymphoblastic leukemia. Ann Hematol. 2006;85:136-8.
108. Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis. 2005;40 Suppl 6:S401-8.
109. Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: A broad-spectrum triazole antifungal. Lancet Infect Dis. 2005;5:775-85.
110. Consigny S, Dhedin N, Datry A, Choquet S, Leblond V, Chosidow O. Successsful voriconazole treatment of disseminated Fusarium infection in an immunocompromised patient. Clin Infect Dis. 2003;37:311-3.
111. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36:1122-31.
112. Baden LR, Katz JT, Fishman JA, et al. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation. 2003;76:1632-7.
113. Cudillo L, Girmenia C, Santilli S, et al. Breakthrough fusariosis in a patient with acute lymphoblastic leukemia receiving voriconazole prophylaxis. Clin Infect Dis. 2005;40:1212-3.
114. Hachem R, Raad I, Afif C, et al. An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungal infections refractory to or intolerant of standard therapy. In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto; 2000.
115. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis. 2006;42:1398-403.
116. Alexander BD, Perfect JR, Daly JS, et al. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. Transplantation. 2008;86:791-6.
117. Ho DY, Lee JD, Rosso F, Montoya JG. Treating disseminated fusariosis: Amphotericin B, voriconazole or both? Mycoses. 2007;50:227-31.
118. Durand-Joly I, Alfandari S, Benchikh Z, et al. Successful outcome of disseminated Fusarium infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia. J Clin Microbiol. 2003;41:4898-900.
119. Apostolidis J, Bouzani M, Platsouka E, et al. Resolution of fungemia due to Fusarium species in a patient with acute leukemia treated with caspofungin. Clin Infect Dis. 2003;36:1349-50.
120. Makowsky MJ, Warkentin DI, Savoie ML. Caspofungin and amphotericin B for disseminated Fusarium verticillioides in leukemia. Ann Pharmacother. 2005;39:1365-6.
121. Neuburger S, Massenkeil G, Seibold M, et al. Successful salvage treatment of disseminated cutaneous fusariosis with liposomal amphotericin B and terbinafine after allogeneic stem cell transplantation. Transpl Infect Dis. 2008;10:290-3.
122. Rothe A, Seibold M, Hoppe T, et al. Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Ann Hematol. 2004;83:394-7.
123. Reuben A, Anaissie E, Nelson PE, et al. Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method. Antimicrob Agents Chemother. 1989;33:1647-9.
124. Hirose H, Terasaki H, Awaya S, Yasuma T. Treatment of fungal corneal ulcers with amphotericin B ointment. Am J Ophthalmol. 1997;124:836-8.
125. Sponsel WE, Graybill JR, Nevarez HL, Dang D. Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br J Ophthalmol. 2002;86:829-30.
126. Rowsey JJ, Acers TE, Smith DL, Mohr JA, Newsom DL, Rodriguez J. Fusarium oxysporum endophthalmitis. Arch Ophthalmol. 1979;97:103-5.
127. Gabriele P, Hutchins RK. Fusarium endophthalmitis in an intravenous drug abuser. Am J Ophthalmol. 1996;122:119-21.
128. Glasgow BJ, Engstrom Jr. RE, Holland GN, Kreiger AE, Wool MG. Bilateral endogenous Fusarium endophthalmitis associated with acquired immunodeficiency syndrome. Arch Ophthalmol. 1996;114:873-7.
129. Durand ML, Kim IK, D'Amico DJ, et al. Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am J Ophthalmol. 2005;140:552-4.
130. Restrepo A. Treatment of tropical mycoses. J Am Acad Dermatol. 1994;31:S91-102.
131. Barret JP, Ramzy PI, Heggers JP, Villareal C, Herndon DN, Desai MH. Topical nystatin powder in severe burns: A new treatment for angioinvasive fungal infections refractory to other topical and systemic agents. Burns. 1999;25:505-8.
132. Guzman-Cottrill JA, Zheng X, Chadwick EG. Fusarium solani endocarditis successfully treated with liposomal amphotericin B and voriconazole. Pediatr Infect Dis J. 2004;23:1059-61.
133. Gupta AK, Baran R, Summerbell RC. Fusarium infections of the skin. Curr Opin Infect Dis. 2000;13:121-8.
134. Dornbusch HJ, Buzina W, Summerbell RC, et al. Fusarium verticillioides abscess of the nasal septum in an immunosuppressed child: case report and identification of the morphologically atypical fungal strain. J Clin Microbiol. 2005;43:1998-2001.
135. Farmaki E, Roilides E. Immunotherapy in patients with systemic mycoses: A promising adjunct. BioDrugs. 2001;15:207-14.
136. Rodriguez-Adrian LJ, Grazziutti ML, Rex JH, Anaissie EJ. The potential role of cytokine therapy for fungal infections in patients with cancer: Is recovery from neutropenia all that is needed? Clin Infect Dis. 1998;26:1270-8.
137. Winn R, Maloukou A, Gil-Lamaignere C, et al. The Eurofung Network. Interferon-gamma and granulocyte-macrophage colony stimulating factor enhance hyphal damage of Aspergillus and Fusarium spp by human neutrophils.. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago; 2001.
138. Gil-Lamaignere C, Winn RM, Simitsopoulou M, Maloukou A, Walsh TJ, Roilides E. Inteferon gamma and granulocyte-macrophage colony-stimulating factor augment the antifungal activity of human polymorphonuclear leukocytes against Scedosporium spp.: comparison with Aspergillus spp. Med Mycol. 2005; 43:253-60.
139. Lewis R, Hogan H, Howell A, Safdar A. Progressive fusariosis: unpredictable posaconazole bioavailability, and feasibility of recombinant interferon-gamma plus granulocyte macrophagecolony stimulating factor for refractory disseminated infection. Leuk Lymphoma. 2008;49:163-5.
140. Cortez KJ, Roilides E, Quiroz-Telles F, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev. 2008;21:157-97.
141. Gilgado F, Cano J, Gene J, Sutton DA, Guarro J. Molecular and phenotypic data supporting distinct species statuses for Scedosporium apiospermum and Pseudallescheria boydii and the proposed new species Scedosporium dehoogii. J Clin Microbiol. 2008;46:766-71.
142. Delhaes L, Harun A, Chen SC, et al. Molecular typing of Australian Scedosporium isolates showing genetic variability and numerous S. aurantiacum. Emerg Infect Dis. 2008;14:282-90.
143. Tadros TS, Workowski KA, Siegel RJ, Hunter S, Schwartz DA. Pathology of hyalohyphomycosis caused by Scedosporium apiospermum (Pseudallescheria boydii): An emerging mycosis. Hum Pathol. 1998;29:1266-72.
144. Rippon J. Pseudallescheriasis. In: Rippon JW, editor. Medical Mycology. 3rd ed. Philadelphia: W. B. Saunders Company; 1988. p. 651-80.
145. Malani AN, Kauffman CA. Changing epidemiology of rare mould infections: Implications for therapy. Drugs. 2007;67:1803-12.
146. Francis P, Walsh TJ. Approaches to management of fungal infections in cancer patients. Oncology (Williston Park). 1992;6:133- 44. discussion 44, 47-8.
147. Corbel MJ, Eades SM. The relative susceptibility of New Zealand black and CBA mice to infection with opportunistic fungal pathogens. Sabouraudia. 1976;14:17-32.
148. Travis LB, Roberts GD, Wilson WR. Clinical significance of Pseudallescheria boydii: A review of 10 years' experience. Mayo Clin Proc. 1985;60:531-7.
149. Kiratli H, Uzun O, Kiraz N, Eldem B. Scedosporium apiospermum chorioretinitis. Acta Ophthalmol Scand. 2001;79:540-2.
150. Wu Z, Ying H, Yiu S, Irvine J, Smith R. Fungal keratitis caused by Scedosporium apiospermum: report of two cases and review of treatment. Cornea. 2002;21:519-23.
151. Mesfin FB, Tobin E, Adamo MA, Dirisio D. Fungal vertebral osteomyelitis due to Scedosporium apiospermum after neardrowning. J Neurosurg Spine. 2008;9:58-61.
152. Garzoni C, Emonet S, Legout L, et al. Atypical infections in tsunami survivors. Emerg Infect Dis. 2005;11:1591-3.
153. Kiraz N, Gulbas Z, Akgun Y, Uzun O. Lymphadenitis caused by Scedosporium apiospermum in an immunocompetent patient. Clin Infect Dis. 2001;32:E59-61.
154. Patterson TF, Andriole VT, Zervos MJ, Therasse D, Kauffman CA. The epidemiology of pseudallescheriasis complicating transplantation: nosocomial and community-acquired infection. Mycoses. 1990;33:297-302.
155. Armin AR, Reddy VB, Orfei E. Fungal endocarditis caused by Pseudallescheria (Petriellidium) boydii in an intravenous drug abuser. Tex Heart Inst J. 1987;14:321-4.
156. Patterson JE. Epidemiology of fungal infections in solid organ transplant patients. Transpl Infect Dis. 1999;1:229-36.
157. Nesky MA, McDougal EC, Peacock Jr. JE. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin Infect Dis. 2000;31:673-7.
158. Husain S, Munoz P, Forrest G, et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis. 2005;40:89-99.
159. Raj R, Frost AE. Scedosporium apiospermum fungemia in a lung transplant recipient. Chest. 2002;121:1714-6.
160. Jabado N, Casanova JL, Haddad E, et al. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. Clin Infect Dis. 1998;27:1437-41.
161. Cimon B, Carrere J, Vinatier JF, Chazalette JP, Chabasse D, Bouchara JP. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis. 2000;19:53-6.
162. Castelli MV, Buitrago MJ, Bernal-Martinez L, Gomez-Lopez A, Rodriguez-Tudela JL, Cuenca-Estrella M. Development and validation of a quantitative PCR assay for diagnosis of scedosporiosis. J Clin Microbiol. 2008;46:3412-6.
163. Meletiadis J, Meis JF, Mouton JW, Rodriquez-Tudela JL, Donnelly JP, Verweij PE. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother. 2002;46:62-8.
164. Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother. 2008;52:1743-50.
165. Gonzalez GM, Tijerina R, Najvar LK, et al. Activity of posaconazole against Pseudallescheria boydii: In vitro and in vivo assays. Antimicrob Agents Chemother. 2003;47:1436-8.
166. Cuenca-Estrella M, Alastruey-Izquierdo A, Alcazar-Fuoli L, et al. In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans. Antimicrob Agents Chemother. 2008;52:1136-9.
167. Heyn K, Tredup A, Salvenmoser S, Muller FM. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother. 2005;49:5157-9.
168. Yustes C, Guarro J. In vitro synergistic interaction between amphotericin B and micafungin against Scedosporium spp. Antimicrob Agents Chemother. 2005;49:3498-500.
169. Caira M, Girmenia C, Valentini CG, et al. Scedosporiosis in patients with acute leukemia: A retrospective multicenter report. Haematologica. 2008;93:104-10.
170. Katragkou A, Dotis J, Kotsiou M, Tamiolaki M, Roilides E. Scedosporium apiospermum infection after near-drowning. Mycoses. 2007;50:412-21.
171. Lamaris GA, Chamilos G, Lewis RE, Safdar A, Raad II, Kontoyiannis DP. Scedosporium infection in a tertiary care cancer center: A review of 25 cases from 1989-2006. Clin Infect Dis. 2006;43:1580-4.
172. Nochez Y, Arsene S, Le Guellec C, et al. Unusual pharmacokinetics of intravitreal and systemic voriconazole in a patient with Scedosporium apiospermum endophthalmitis. J Ocul Pharmacol Ther. 2008;24:87-90.
173. Mellinghoff IK, Winston DJ, Mukwaya G, Schiller GJ. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis. 2002;34:1648-50.
174. Abzug MJ, Walsh TJ. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J. 2004;23:769-73.
175. Cooley L, Spelman D, Thursky K, Slavin M. Infection with Scedosporium apiospermum and S. prolificans, Australia. Emerg Infect Dis. 2007;13:1170-7.
176. Perfect JR, Schell WA. The new fungal opportunists are coming. Clin Infect Dis. 1996;22 Suppl 2:S112-8.
177. Roilides E, Simitsopoulou M, Katragkou A, Walsh TJ. Host immune response against Scedosporium species. Med Mycol. 2009;47:433-40.
178. Ortoneda M, Capilla J, Pujol I, et al. Liposomal amphotericin B and granulocyte colony-stimulating factor therapy in a murine model of invasive infection by Scedosporium prolificans. J Antimicrob Chemother. 2002;49:525-9.
179. Berenguer J, Rodriguez-Tudela JL, Richard C, et al. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium prolificans Spanish Study Group. Medicine (Baltimore). 1997;76:256-65.
180. Rodriguez-Tudela JL, Berenguer J, Guarro J, et al. Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol. 2009;47:359-70.
181. Carreter de Granda ME, Richard C, Conde E, et al. Endocarditis caused by Scedosporium prolificans after autologous peripheral blood stem cell transplantation. Eur J Clin Microbiol Infect Dis. 2001;20:215-7.
182. Lopez L, Gaztelurrutia L, Cuenca-Estrella M, et al. Infection and colonization by Scedosporium prolificans. Enferm Infecc Microbiol Clín. 2001;19:308-13.
183. Salkin IF, McGinnis MR, Dykstra MJ, Rinaldi MG. Scedosporium inflatum, an emerging pathogen. J Clin Microbiol. 1988;26: 498-503.
184. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL. Head-to-head comparison of the activities of currently available antifungal agents against 3, 378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother. 2006;50:917-21.
185. Del Poeta M, Schell WA, Perfect JR. In vitro antifungal activity of pneumocandin L-743, 872 against a variety of clinically important molds. Antimicrob Agents Chemother. 1997;41:1835-6.
186. McGinnis MR, Pasarell L, Sutton DA, Fothergill AW, Cooper Jr. CR, Rinaldi MG. In vitro activity of voriconazole against selected fungi. Med Mycol. 1998;36:239-42.
187. Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother. 2001;45:2151-3.
188. Afeltra J, Dannaoui E, Meis JF, Rodriguez-Tudela JL, Verweij PE. In vitro synergistic interaction between amphotericin B and pentamidine against Scedosporium prolificans. Antimicrob Agents Chemother. 2002;46:3323-6.
189. Meletiadis J, Mouton JW, Rodriguez-Tudela JL, Meis JF, Verweij PE. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob Agents Chemother. 2000;44:470-2.
190. Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother. 2003;47:106-17.
191. Rodriguez MM, Calvo E, Serena C, Marine M, Pastor FJ, Guarro J. Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans. Antimicrob Agents Chemother. 2009;53:2153-5.
192. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J. 2002;21:240-8.
193. Tong SY, Peleg AY, Yoong J, Handke R, Szer J, Slavin M. Breakthrough Scedosporium prolificans infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient. Transpl Infect Dis. 2007;9:241-3.
194. Ananda-Rajah MR, Grigg A, Slavin MA. Breakthrough disseminated Scedosporium prolificans infection in a patient with relapsed leukaemia on prolonged voriconazole followed by posaconazole prophylaxis. Mycopathologia. 2008;166:83-6.
195. Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis. 2003;22:111-3.
196. Li JY, Yong TY, Grove DI, Coates PT. Successful control of Scedosporium prolificans septic arthritis and probable osteomyelitis without radical surgery in a long-term renal transplant recipient. Transpl Infect Dis. 2008;10:63-5.
197. Steinbach WJ, Schell WA, Miller JL, Perfect JR. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J Clin Microbiol. 2003;41:3981-5.
198. Kesson AM, Bellemore MC, O'Mara TJ, Ellis DH, Sorrell TC. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with a novel agent, hexadecylphospocholine (miltefosine), in combination with terbinafine and voriconazole: A case report. Clin Infect Dis. 2009;48:1257-61.
199. Guarro J, Gams W, Pujol I, Gene J. Acremonium species: new emerging fungal opportunists-in vitro antifungal susceptibilities and review. Clin Infect Dis. 1997;25:1222-9.
200. Fridkin SK, Kremer FB, Bland LA, Padhye A, McNeil MM, Jarvis WR. Acremonium kiliense endophthalmitis that occurred after cataract extraction in an ambulatory surgical center and was traced to an environmental reservoir. Clin Infect Dis. 1996;22:222-7.
201. Pastorino AC, Menezes UP, Marques HH, et al. Acremonium kiliense infection in a child with chronic granulomatous disease. Braz J Infect Dis. 2005;9:529-34.
202. Schell WA, Perfect JR. Fatal, disseminated Acremonium strictum infection in a neutropenic host. J Clin Microbiol. 1996;34:1333-6.
203. Anadolu R, Hilmioglu S, Oskay T, Boyvat A, Peksari Y, Gurgey E. Indolent Acremonium strictum infection in an immunocompetent patient. Int J Dermatol. 2001;40:451-3.
204. Keynan Y, Sprecher H, Weber G. Acremonium vertebral osteomyelitis: Molecular diagnosis and response to voriconazole. Clin Infect Dis. 2007;45:e5-6.
205. Roilides E, Bibashi E, Acritidou E, et al. Acremonium fungemia in two immunocompromised children. Pediatr Infect Dis J. 1995;14:548-50.
206. Fincher RM, Fisher JF, Lovell RD, Newman CL, Espinel-Ingroff A, Shadomy HJ. Infection due to the fungus Acremonium (cephalosporium). Medicine (Baltimore). 1991;70:398-409.
207. Chang YH, Huang LM, Hsueh PR, et al. Acremonium pyomyositis in a pediatric patient with acute leukemia. Pediatr Blood Cancer. 2005;44:521-4.
208. Sener AG, Yucesoy M, Senturkun S, Afsar I, Yurtsever SG, Turk M. A case of Acremonium strictum peritonitis. Med Mycol. 2008;46:495-7.
209. Yalaz M, Hilmioglu S, Metin D, et al. Fatal disseminated Acremonium strictum infection in a preterm newborn: A very rare cause of neonatal septicaemia. J Med Microbiol. 2003;52:835-7.
210. Yamazaki R, Mori T, Aisa Y, et al. Systemic infection due to Acremonium after allogeneic peripheral blood stem cell transplantation. Intern Med. 2006;45:989-90.
211. Miyakis S, Velegraki A, Delikou S, et al. Invasive Acremonium strictum infection in a bone marrow transplant recipient. Pediatr Infect Dis J. 2006;25:273-5.
212. Weissgold DJ, Maguire AM, Brucker AJ. Management of postoperative Acremonium endophthalmitis. Ophthalmology. 1996; 103:749-56.
213. Filipello Marchisio V, Fusconi A. Morphological evidence for keratinolytic activity of Scopulariopsis spp. isolates from nail lesions and the air. Med Mycol. 2001;39:287-94.
214. Steinbach WJ, Schell WA, Miller JL, Perfect JR, Martin PL. Fatal Scopulariopsis brevicaulis infection in a paediatric stem-cell transplant patient treated with voriconazole and caspofungin and a review of Scopulariopsis infections in immunocompromised patients. J Infect. 2004;48:112-6.
215. Shankar EM, Vignesh R, Barton RC, et al. Hydrothorax in association with Scopulariopsis brumptii in an AIDS patient in Chennai, India. Trans R Soc Trop Med Hyg. 2007;101:1270-2.
216. Aydin S, Ertugrul B, Gultekin B, Uyar G, Kir E. Treatment of two postoperative endophthalmitis cases due to Aspergillus flavus and Scopulariopsis spp. with local and systemic antifungal therapy. BMC Infect Dis. 2007;7:87.
217. Vollmer T, Stormer M, Kleesiek K, Dreier J. Evaluation of novel broad-range real-time PCR assay for rapid detection of human pathogenic fungi in various clinical specimens. J Clin Microbiol. 2008;46:1919-26.
218. Isidro AM, Amorosa V, Stopyra GA, Rutenberg HL, Pentz WH, Bridges CR. Fungal prosthetic mitral valve endocarditis caused by Scopulariopsis species: case report and review of the literature. J Thorac Cardiovasc Surg. 2006;131:1181-3.
219. Sellier P, Monsuez JJ, Lacroix C, et al. Recurrent subcutaneous infection due to Scopulariopsis brevicaulis in a liver transplant recipient. Clin Infect Dis. 2000;30:820-3.
220. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL. Scopulariopsis brevicaulis, a fungal pathogen resistant to broad-spectrum antifungal agents. Antimicrob Agents Chemother. 2003;47:2339-41.
221. Carrillo-Munoz AJ, Giusiano G, Guarro J, et al. In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis. Int J Antimicrob Agents. 2007;30:157-61.
222. Cuenca-Estrella M, Gomez-Lopez A, Buitrago MJ, Mellado E, Garcia-Effron G, Rodriguez-Tudela JL. In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis. Antimicrob Agents Chemother. 2006;50:2248-50.
223. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Garcia-Effron G, Monzon A, Rodriguez-Tudela JL. In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi. Antimicrob Agents Chemother. 2005;49:5136-8.
224. Wagner D, Sander A, Bertz H, Finke J, Kern WV. Breakthrough invasive infection due to Debaryomyces hansenii (teleomorph Candida famata) and Scopulariopsis brevicaulis in a stem cell transplant patient receiving liposomal amphotericin B and caspofungin for suspected aspergillosis. Infection. 2005;33:397-400.
225. Patel R, Gustaferro CA, Krom RA, Wiesner RH, Roberts GD, Paya CV. Phaeohyphomycosis due to Scopulariopsis brumptii in a liver transplant recipient. Clin Infect Dis. 1994;19:198-200.
226. Kriesel JD, Adderson EE, Gooch 3rd WM, Pavia AT. Invasive sinonasal disease due to Scopulariopsis candida: case report and review of scopulariopsosis. Clin Infect Dis. 1994;19:317-9.
227. Lovell RD, Moll M, Allen J, Cicci LG. Disseminated Paecilomyces lilacinus infection in a patient with AIDS. AIDS Read. 2002; 12:212-3. 8, 21.
228. Safdar A. Progressive cutaneous hyalohyphomycosis due to Paecilomyces lilacinus: rapid response to treatment with caspofungin and itraconazole. Clin Infect Dis. 2002;34:141-57.
229. Van Schooneveld T, Freifeld A, Lesiak B, Kalil A, Sutton DA, Iwen PC. Paecilomyces lilacinus infection in a liver transplant patient: case report and review of the literature. Transpl Infect Dis. 2008;10:117-22.
230. Gutierrez-Rodero F, Moragon M, Ortiz de laTabla V, Mayol MJ, Martin C. Cutaneous hyalohyphomycosis caused by Paecilomyces lilacinus in an immunocompetent host successfully treated with itraconazole: case report and review. Eur J Clin Microbiol Infect Dis. 1999;18:814-8.
231. Clark NM. Paecilomyces lilacinus infection in a heart transplant recipient and successful treatment with terbinafine. Clin Infect Dis. 1999;28:1169-70.
232. Orth B, Frei R, Itin PH, et al. Outbreak of invasive mycoses caused by Paecilomyces lilacinus from a contaminated skin lotion. Ann Intern Med. 1996;125:799-806.
233. Pastor FJ, Guarro J. Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections. Clin Microbiol Infect. 2006;12:948-60.
234. Wessolossky M, Haran JP, Bagchi K. Paecilomyces lilacinus olecranon bursitis in an immunocompromised host: case report and review. Diagn Microbiol Infect Dis. 2008;61:354-7.
235. Shing MM, Ip M, Li CK, Chik KW, Yuen PM. Paecilomyces varioti fungemia in a bone marrow transplant patient. Bone Marrow Transplant. 1996;17:281-3.
236. Lionakis MS, Bodey GP, Tarrand JJ, Raad II, Kontoyiannis DP. The significance of blood cultures positive for emerging saprophytic moulds in cancer patients. Clin Microbiol Infect. 2004;10:922-5.
237. Aguilar C, Pujol I, Sala J, Guarro J. Antifungal susceptibilities of Paecilomyces species. Antimicrob Agents Chemother. 1998; 42:1601-4.
238. Gottlieb T, Atkins BL. Case report. Successful treatment of cutaneous Paecilomyces lilacinus infection with oral itraconazole in an immune competent host. Mycoses. 2001;44:513-5.
239. Das A, MacLaughlin EF, Ross LA, et al. Paecilomyces variotii in a pediatric patient with lung transplantation. Pediatr Transplant. 2000;4:328-32.
240. Ortoneda M, Capilla J, Pastor FJ, et al. In vitro interactions of approved and novel drugs against Paecilomyces spp. Antimicrob Agents Chemother. 2004;48:2727-9.
241. Chan-Tack KM, Thio CL, Miller NS, Karp CL, Ho C, Merz WG. Paecilomyces lilacinus fungemia in an adult bone marrow transplant recipient. Med Mycol. 1999;37:57-60.
242. Hilmarsdottir I, Thorsteinsson SB, Asmundsson P, Bodvarsson M, Arnadottir M. Cutaneous infection caused by Paecilomyces lilacinus in a renal transplant patient: Treatment with voriconazole. Scand J Infect Dis. 2000;32:331-2.
243. Mullane K, Toor AA, Kalnicky C, Rodriguez T, Klein J, Stiff P. Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections. Transpl Infect Dis. 2007; 9:89-96.
244. Wang SM, Shieh CC, Liu CC. Successful treatment of Paecilomyces variotii splenic abscesses: A rare complication in a previously unrecognized chronic granulomatous disease child. Diagn Microbiol Infect Dis. 2005;53:149-52.
245. Ford JG, Agee S, Greenhaw ST. Successful medical treatment of a case of Paecilomyces lilacinus keratitis. Cornea. 2008; 27:1077-9.
246. Stillwell WT, Rubin BD, Axelrod JL. Chrysosporium, a new causative agent in osteomyelitis. A case report. Clin Orthop Relat Res 1984:184:190-2.
247. Levy FE, Larson JT, George E, Maisel RH. Invasive Chrysosporium infection of the nose and paranasal sinuses in an immunocompromised host. Otolaryngol Head Neck Surg. 1991;104:384-8.
248. Warwick A, Ferrieri P, Burke B, Blazar BR. Presumptive invasive Chrysosporium infection in a bone marrow transplant recipient. Bone Marrow Transplant. 1991;8:319-22.
249. Munoz FM, Demmler GJ, Travis WR, Ogden AK, Rossmann SN, Rinaldi MG. Trichoderma longibrachiatum infection in a pediatricpatient with aplastic anemia. J Clin Microbiol. 1997; 35:499-503.
250. Roilides E, Sigler L, Bibashi E, Katsifa H, Flaris N, Panteliadis C. Disseminated infection due to Chrysosporium zonatum in a patient with chronic granulomatous disease and review of non-Aspergillus fungal infections in patients with this disease. J Clin Microbiol. 1999;37:18-25.
251. Wagoner MD, Badr IA, Hidayat AA. Chrysosporium parvum keratomycosis. Cornea. 1999;18:616-20.
252. Lagrange-Xelot M, Schlemmer F, Gallien S, Lacroix C, Molina JM. Trichoderma fungaemia in a neutropenic patient with pulmonary cancer and human immunodeficiency virus infection. Clin Microbiol Infect. 2008;14:1190-2.
253. Kviliute R, Paskevicius A, Gulbinovic J, Stulpinas R, Griskevicius L. Nonfatal Trichoderma citrinoviride pneumonia in an acute myeloid leukemia patient. Ann Hematol. 2008;87:501-2.
254. Maran AG, Kwong K, Milne LJ, Lamb D. Frontal sinusitis caused by Myriodontium keratinophilum. Br Med J (Clin Res Ed). 1985;290:207.
255. Ahmad S, Johnson RJ, Hillier S, Shelton WR, Rinaldi MG. Fungal peritonitis caused by Lecythophora mutabilis. J Clin Microbiol. 1985;22:182-6.
256. Jacobs F, Byl B, Bourgeois N, et al. Trichoderma viride infection in a liver transplant recipient. Mycoses. 1992;35:301-3.
257. Farina C, Vailati F, Manisco A, Goglio A. Fungaemia survey: A 10-year experience in Bergamo, Italy. Mycoses. 1999;42:543-8.
258. Chin-Hong PV, Sutton DA, Roemer M, Jacobson MA, Aberg JA. Invasive fungal sinusitis and meningitis due to Arthrographis kalrae in a patient with AIDS. J Clin Microbiol. 2001;39:804-7.
259. Henke MO, De Hoog GS, Gross U, Zimmermann G, Kraemer D, Weig M. Human deep tissue infection with an entomopathogenic Beauveria species. J Clin Microbiol. 2002;40:2698-702.
260. Suh MK, Lim JW, Lee YH, et al. Subcutaneous hyalohyphomycosis due to Cephalotheca foveolata in an immunocompetent host. Br J Dermatol. 2006;154:1184-9.
261. Chouaki T, Lavarde V, Lachaud L, Raccurt CP, Hennequin C. Invasive infections due to Trichoderma species: report of 2 cases, findings of in vitro susceptibility testing, and review of the literature. Clin Infect Dis. 2002;35:1360-7.
262. Loeppky CB, Sprouse RF, Carlson JV, Everett ED. Trichoderma viride peritonitis. South Med J. 1983;76:798-9.
263. Furukawa H, Kusne S, Sutton DA, et al. Acute invasive sinusitis due to Trichoderma longibrachiatum in a liver and small bowel transplant recipient. Clin Infect Dis. 1998;26:487-9.
264. Richter S, Cormican MG, Pfaller MA, et al. Fatal disseminated Trichoderma longibrachiatum infection in an adult bone marrow transplant patient: Species identification and review of the literature. J Clin Microbiol. 1999;37:1154-60.
265. Hennequin C, Chouaki T, Pichon JC, Strunski V, Raccurt C. Otitis externa due to Trichoderma longibrachiatum. Eur J Clin Microbiol Infect Dis. 2000;19:641-2.
266. Kratzer C, Tobudic S, Schmoll M, Graninger W, Georgopoulos A. In vitro activity and synergism of amphotericin B, azoles and cationic antimicrobials against the emerging pathogen Trichoderma spp. J Antimicrob Chemother. 2006;58:1058-61.
267. De Miguel D, Gomez P, Gonzalez R, et al. Nonfatal pulmonary Trichoderma viride infection in an adult patient with acute myeloid leukemia: report of one case and review of the literature. Diagn Microbiol Infect Dis. 2005;53:33-7.